TerminatedPhase 2

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Stopped: Terminated per directive from Bayer due to funding.

United States1 participantsStarted 2024-06-26

Plain-language summary

This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Histologically confirmed mismatch repair deficient or microsatellite instability high advanced stage colorectal cancer
. Measurable disease (per RECIST v1.1)
. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
. Age \> 18
. The patient must be able to swallow oral medication.
. Adequate organ function based on the following lab assessments:
. ANC must be ≥ 1500/mm3
. platelet count must be ≥ 100,000/mm3

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Objective Response Rate (ORR), Lead-in Phase

Timeframe: Up to 12 months (lead-in phase)

Progression-free Survival (PFS), Randomize Phase

Timeframe: Up to 24 months

Trial details

NCT IDNCT06006923

SponsorAnwaar Saeed

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-11

View on ClinicalTrials.gov More MSI-H Colorectal Cancer trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Histologically confirmed mismatch repair deficient or microsatellite instability high advanced stage colorectal cancer
. Measurable disease (per RECIST v1.1)
. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
. Age \> 18
. The patient must be able to swallow oral medication.
. Adequate organ function based on the following lab assessments:
. ANC must be ≥ 1500/mm3
. platelet count must be ≥ 100,000/mm3

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Exclusion criteria